NCT02452814View on ClinicalTrials.gov

Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection

CompletedOBSERVATIONAL
Enrollment

8

Participants

Timeline

Start Date

May 7, 2014

Primary Completion Date

May 3, 2017

Study Completion Date

May 3, 2017

Conditions
HCV
Trial Locations (3)

75203

Methodist Transplant Physicians, Dallas

77030

Research Specialists of Texas, Houston

00927

Fundacion de Investigacion de Diego, San Juan

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02452814 - Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection | Biotech Hunter | Biotech Hunter